Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia 3Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 17Cytarabine 11venetoclax 9fludarabine 9Mycophenolic Acid 8Busulfan 7fludarabine phosphate 6Whole-Body Irradiation 6ruxolitinib 5Tacrolimus 5Methotrexate 5Daunorubicin 5Cyclosporine 5Azacitidine 5ponatinib 4Vincristine 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Etoposide 4Dexamethasone 4blinatumomab 3asciminib 3Prednisone 3Mercaptopurine 3Inotuzumab Ozogamicin 3Doxorubicin 3revumenib 2quizartinib 2pegfilgrastim 2pegaspargase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia × Inotuzumab Ozogamicin × 90 days × Clear all
NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
27 enrolled
Other hematologic neoplasm

Leukemia

NCT05748171 2026-05-14

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Pfizer

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04747912 2026-03-30

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

University of Chicago

Phase 2 Suspended
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡